Addictions, Drug & Alcohol Institute

ADAI News & Events

December 5, 2022

High THC Policy | Final Report: Exploring Policy Solutions (DRAFT report)

High THC Policy | Final Report (DRAFT): Exploring Policy Solutions to Address Public Health Challenges of High THC Products. Draft report by the ADAI CERP

To address this emerging public safety challenge of increasingly available high-THC products (e.g. dabs, wax, concentrates), the WA State Health Care Authority was directed by ESSB 5092 (2021) to contract with the University of Washington’s Addictions, Drug & Alcohol Institute (ADAI) to identify areas of common ground and consensus, and develop recommendations for state policies related to cannabis concentration…

Join the ADAI CERP Team: Seeking Full-Time Program Evaluator

ADAI is Hiring! Research Scientist/Program Evaluator for CERP (full-time)

The Cannabis Education & Research Program (CERP) at the Addictions, Drug & Alcohol Institute (ADAI), which is partially funded by the WA State Dedicated Cannabis Fund for research at the UW (since 2015), is seeking a full-time Program Evaluator (official title: Research Scientist/Engineer) to support its work responding to emerging research and information needs of…

December 1, 2022

Substance Use is a Health Issue, Not a Legal One – Op-Ed in the Seattle Times by Dr. Caleb Banta-Green

Seattle Times Logo

ADAI Acting Professor Caleb Banta-Green, PhD authored an opinion piece published in the Seattle Times on November 30, 2022 urging the Washington State Legislature and governor to act on recommendations made by the state’s Substance Use Recovery Services Advisory (SURSA) Committee. The SURSA Committee, created by a 2021 state law, ESB-5476, was tasked with developing…

November 30, 2022

ADAI CERP Report to Legislature Details Public Health Risks for High-THC Cannabis

ADAI CERP Report to WA Legislature about High-THC Cannabis

In early fall, ADAI Acting Associate Professor Beatriz Carlini, PhD, MPH and her team at the Cannabis Education & Research Program (CERP) published and delivered a report to the Washington State legislature that addresses the public health challenges of cannabis products with high concentrations of THC, the psychoactive ingredient in cannabis that causes a “high.”…

November 29, 2022

ADAI Lunch & Learn: Screening & Treating Cannabis Use Disorder in Primary Care (Dec. 6, 12pm PT)

ADAI Lunch & Learn

Join ADAI and presenter Tessa Matson, MPH (PhD Candidate), UW School of Public Health, for our December Lunch & Learn session:  Evaluation of Screening, Assessment, Diagnosis and Treatment for Cannabis Use Disorder in Primary CareDecember 6, 202212-1pm PTRegister here Nearly 44 million people use cannabis in the past year, and of those, 21% use cannabis daily….

November 23, 2022

New from ADAI: Provider Perspectives on Medication Treatment for OUD in Adolescents

New from ADAI: Perspectives on Medication Treatment for OUD in Adolescents: Results from a Provider Learning Series. Peavy KM, Adwell A, Owens MD, Banta-Green CJ. Subst Use Misuse 2022 (in press)

Despite recent surges in adolescent opioid use disorder (OUD), teens are less likely to enter treatment compared to adults, and are rarely in treatment settings that offer evidence-based medication treatment (methadone, buprenorphine, and naltrexone). Buprenorphine is the only medication approved for people under 18 (aged 16 and older) and methadone requires written parental consent for…

November 10, 2022

Looking for ADAI Events?

Photo of person holding phone in one hand and writing on calendar with other

Looking for upcoming events hosted by the UW Addictions, Drug & Alcohol Institute? You can find our events a few different ways: Subscribe to the ADAI News & Events blog (this!) and get notices about events hosted by ADAI and its various centers and teams (CEDEER, CAAHS and the Northwest ATTC, CERP, CTN, and more!),…

November 8, 2022

New ADAI Report: Overdose Deaths Involving Prescription Opioids in WA, 2010-2021

New ADAI report: Overdose deaths involving pharmaceutical opioids in WA State from 2010-2021

This new report by Caleb Banta-Green, PhD, MPH, MSW and Jason Williams, PhD of the ADAI Center for Community-Engaged Drug Education, Epidemiology & Research (CEDEER) examines key indicators related to pharmaceutical opioids including sales data and overdose death rates. Key Points Prescription opioid overdose deaths declined from their peak in 2006, but are higher than…

November 7, 2022

New Research from ADAI: Opioid Safety Intervention for Community Pharmacists

New Research from ADAI

ADAI Research Associate Professor Anthony Floyd, PhD has a new paper out describing an assessment of community pharmacists’ readiness to implement an educational program that aims to boost their knowledge and confidence when it comes to providing opioid safety and harm reduction services to patients and customers. What is the context for this study? Community…

November 4, 2022

How Can We Solve King County’s Fentanyl Problem? Seattle Met Article Feat. Caleb Banta-Green

Seattle Met: How Can We Solve King County's Fentanyl Problem?

Seattle Met magazine has two new stories about fentanyl in King County, both by Angela Cabotaje. The first, “How Can We Solve King County’s Fentanyl Problem?,” features ADAI Acting Professor Caleb Banta-Green, PhD, MPH, MSW, describing the impact pharmaceutical companies had on the opioid overdose crisis, and the innovative program Bupe Pathways, which is helping…

Next page